(Total Views: 71)
Posted On: 10/20/2023 2:20:46 PM
Post# of 27273

$MRK News Article - Merck's KEYTRUDA (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer https://marketwirenews.com/news-releases/merc...74323.html


My Twitter: WhyteStocks